TrialInternational journal of hematology2019

Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation.

Kenshi Suzuki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.